Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib cream versus mometasone cream for mild to moderate vitiligo
IRCT20150706023081N5Phase 3Not yet recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Vitiligo comparing Baricitinib cream with Mometasone cream (2 arms). Primary endpoint: Extent of disease improvement. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
baricitinibmometasone
03
Conditions
Vitiligo
Beyond the preview
Go deeper on IRCT20150706023081N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150706023081N5.